Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?
Yıl: 2023 Cilt: 71 Sayı: 1 Sayfa Aralığı: 34 - 40 Metin Dili: İngilizce DOI: 10.5578/tt.20239905 İndeks Tarihi: 30-05-2023
Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?
Öz: Introduction: The genetic risk factors for Coronavirus disease-2019 (COVID- 19)-associated pulmonary fibrosis (CAPF) are not clearly defined. Mutations in the genes encoding telomerase reverse transcriptase (TERT) and mucin 5B (MUC5B) are well-known genetic risk factors for pulmonary fibrosis. In this study, we aimed to show whether the most common proven mutations of pulmonary fibrosis affect the development of CAPF. Materials and Methods: Forty-eight patients who were matched for age, gen- der, COVID-19 disease severity, and respiratory support type and needed high flow nasal cannula, non-invasive mechanical ventilator, or invasive mechanical ventilator due to COVID-19 were followed up prospectively. Eighteen patients were excluded from the follow-up due to known structural lung disease, col- lagen tissue disease, and occupational exposure to fibrosis. The patients were called for follow-up three months after discharge, and CT was performed. Those with fibrosis (n= 15) in the third-month follow-up CT were included in the CAPF group, and those with complete resolution (n= 15) were included in the control group. Blood samples were taken for genetic analysis. Results: TERT gene study revealed that six (40%) of the fibrosis group was normal, while five were heterozygous (33.3%). MUC5B polymorphism was not detected in 10 (66.7%) of the fibrosis group. Conclusion: Individuals with TERT mutations may be at a higher risk for CAPF. Further studies are needed to clarify the genetic risk factors for CAPF.
Anahtar Kelime: MUC5B ve TERT mutasyonları şiddetli COVID-19 olan bireylerde pulmoner fibrozis için genetik risk faktörleri midir?
Öz: Giriş: Koronovirüs hastalığı-2019 (COVID-19) ile ilişkili pulmoner fibroz (CAPF) için genetik risk faktörleri net olarak tanımlanmamış- tır. Telomeraz ters transkriptaz (TERT) ve müsin 5B (MUC5B) kodlayan genlerdeki mutasyonlar, pulmoner fibroz için iyi bilinen genetik risk faktörleridir. Bu çalışmada pulmoner fibrozisin kanıtlanmış en yaygın mutasyonlarının CAPF gelişimi üzerine etkisinin olup olmadığını göstermeyi amaçladık. Materyal ve Metod: Yaş, cinsiyet, COVID-19 hastalık şiddeti ve solunum destek tipi açısından uyumlu ve COVID-19 nedeniyle yüksek akımlı nazal kanül, non-invaziv mekanik ventilatör veya invaziv mekanik ventilatör ihtiyacı olan 48 hasta prospektif olarak izlendi. On sekiz hasta, bilinen yapısal akciğer hastalığı, kollajen doku hastalığı ve mesleki fibrozise maruz kalma nedeniyle takipten çıkarıldı. Hastalar taburcu olduktan üç ay sonra kontrole çağrılarak BT çekildi. Üçüncü ay kontrol BT’sinde fibrozis (n= 15) olanlar CAPF grubuna, rezolüsyonu tam olanlar (n= 15) kontrol grubuna eklendi. Genetik analiz için kan örnekleri alındı. Bulgular: Fibrozis grubunun altısında (%40) TERT gen analizi normal, beşinde (%33,3) heterozigot bulundu. Fibrozis grubunun 10’unda (%66,7) MUC5B polimorfizmi saptanmadı. Sonuç: TERT mutasyonları olan kişiler CAPF için daha yüksek risk altında olabilir. CAPF için genetik risk faktörlerini netleştirmek için daha fazla çalışmaya ihtiyaç vardır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379(9828): 1835-46. https://doi.org/10.1016/S0140-6736(11)61904-1
- 2. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 Long-term effects of COVID-19: A systematic review and meta-anal- ysis. Sci Rep 2021; 11: 16144. https://doi.org/10.1038/ s41598-021-95565-8
- 3. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: A longitudinal study. Radiology 2020; 296(2): e55-64. https://doi.org/10.1148/radi- ol.2020200843
- 4. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med 2020; 8(8): 807-15. https://doi. org/10.1016/S2213-2600(20)30225-3
- 5. Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies. Pulm Med 2020; 2020: 6175964. https://doi.org/10.1155/2020/6175964
- 6. Huang W, Wu Q, Chen Z, Xiong Z, Wang K, Tian J, et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect 2021; 82(2): e5-7. https:// doi.org/10.1016/j.jinf.2020.09.027
- 7. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idio- pathic pulmonary fibrosis. N Engl J Med 2007; 356(13): 1317-26. https://doi.org/10.1056/NEJMoa066157
- 8. Farghaly S, Badedi M, Ibrahim R, Sadhan MH, Alamoudi A, Alnami A, et al. Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study. Medicine 2022; 101(3): e28639. https://doi.org/10.1097/ MD.0000000000028639
- 9. Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 2017; 27(3): 342-9. https://doi.org/10.4103/ijri. IJRI_469_16
- 10. Mineo G, Ciccarese F, Modolon C, Landini MP, Valentino M, Zompatori M. Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: Role of follow-up CT. Radiol Med 2012; 117(2): 185-200. https://doi.org/10.1007/s11547- 011-0740-3
- 11. Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treat- ment. Ann Am Thorac Soc 2021; 18(5): 799-806. https:// doi.org/10.1513/AnnalsATS.202008-1002OC
- 12. Singh R, Gaziano D. Functional and radiological improve- ment in a COVID-19 pneumonia patient treated with ste- roids. Cureus 2021; 13(5): e15257. https://doi. org/10.7759/cureus.15257
- 13. Yetkin NA, Tutar N. An another cause of COVID-19 related pulmonary fibrosis: The high oxygen supplement. Tuberk Toraks 2022; 70(2): 203-5. https://doi.org/10.5578/ tt.20229811
| APA | Yetkin N, Kiraz A, baran ketencioğlu b, bol c, tutar n (2023). Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. , 34 - 40. 10.5578/tt.20239905 |
| Chicago | Yetkin Nur Aleyna,Kiraz Aslihan,baran ketencioğlu burcu,bol canan,tutar nuri Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. (2023): 34 - 40. 10.5578/tt.20239905 |
| MLA | Yetkin Nur Aleyna,Kiraz Aslihan,baran ketencioğlu burcu,bol canan,tutar nuri Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. , 2023, ss.34 - 40. 10.5578/tt.20239905 |
| AMA | Yetkin N,Kiraz A,baran ketencioğlu b,bol c,tutar n Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. . 2023; 34 - 40. 10.5578/tt.20239905 |
| Vancouver | Yetkin N,Kiraz A,baran ketencioğlu b,bol c,tutar n Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. . 2023; 34 - 40. 10.5578/tt.20239905 |
| IEEE | Yetkin N,Kiraz A,baran ketencioğlu b,bol c,tutar n "Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?." , ss.34 - 40, 2023. 10.5578/tt.20239905 |
| ISNAD | Yetkin, Nur Aleyna vd. "Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?". (2023), 34-40. https://doi.org/10.5578/tt.20239905 |
| APA | Yetkin N, Kiraz A, baran ketencioğlu b, bol c, tutar n (2023). Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. Tüberküloz ve Toraks, 71(1), 34 - 40. 10.5578/tt.20239905 |
| Chicago | Yetkin Nur Aleyna,Kiraz Aslihan,baran ketencioğlu burcu,bol canan,tutar nuri Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. Tüberküloz ve Toraks 71, no.1 (2023): 34 - 40. 10.5578/tt.20239905 |
| MLA | Yetkin Nur Aleyna,Kiraz Aslihan,baran ketencioğlu burcu,bol canan,tutar nuri Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. Tüberküloz ve Toraks, vol.71, no.1, 2023, ss.34 - 40. 10.5578/tt.20239905 |
| AMA | Yetkin N,Kiraz A,baran ketencioğlu b,bol c,tutar n Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. Tüberküloz ve Toraks. 2023; 71(1): 34 - 40. 10.5578/tt.20239905 |
| Vancouver | Yetkin N,Kiraz A,baran ketencioğlu b,bol c,tutar n Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?. Tüberküloz ve Toraks. 2023; 71(1): 34 - 40. 10.5578/tt.20239905 |
| IEEE | Yetkin N,Kiraz A,baran ketencioğlu b,bol c,tutar n "Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?." Tüberküloz ve Toraks, 71, ss.34 - 40, 2023. 10.5578/tt.20239905 |
| ISNAD | Yetkin, Nur Aleyna vd. "Are MUC5B and TERT mutations genetic risk factors for pulmonary fibrosis in individuals with severe COVID-19?". Tüberküloz ve Toraks 71/1 (2023), 34-40. https://doi.org/10.5578/tt.20239905 |
